Avant to fund up to $20M, forms 50/50 JV with Ainnova for retina AI tech

AVAI BIO, INC.

Avant contributes up to $20M in capital over 12 months to new JV 'Ai-Nova Acquisition Corp'.
Ainnova contributes Vision AI technology portfolio for retinal disease detection and scanning.
Ownership split 50% Avant, 50% Ainnova; JV to issue 2,000,000 shares.
Profit distribution: first to Ainnova for contributed business value, then Avant for capital, then pro-rata.
Territories include US, Canada, Europe; JV to seek third-party licensing and strategic transactions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.